Sarepta Therapeutics

Biotech · Public

exon-skipping gene therapy for Duchenne muscular dystrophy

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · sarepta.com

Sector: Biotech
Latest Form D: $400M, Feb 2020
Total capital: $599M

Federal grants: None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised: $430M; 2 Form D · last Feb 2020; 80 months since last filing
Federal contracts: $169M; 7 awards · Defense; Rank in Biotech#7 of 4373
Granted patents: 10; 30 pending · first 2025; Rank in peer group#16 of 1449

Capital timeline

Latest events

Feb 2020Private capital raisedForm D · SEC · 2nd filing$400M
Nov 2019Private capital raisedForm D · SEC · 1st filing$30.5M
Aug 2012Federal contractDefense · Im Formulation Feasiblity Study$3.8M
Nov 2011Federal contractDefense · Antibacterial And Anti-shiga$100K
Mar 2011Federal contractDefense · The Transformational Medical$99K
Jul 2010Federal contractDefense · Advanced Development Of Hemorrhagic$106M
Jun 2010Federal contractDefense · H1N1 Countermeasure Development$12.3M

Show 2 earlier federal awards

May 2009Federal contractDefense · Non-personal Services$7.7M
Nov 2006Federal contractDefense · A New Antiviral (antisense)$38.4M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

156months

from Sarepta Therapeutics’s first federal award to its first private round.

First federal award · Nov 2006: Defense · $38.4M
First Form D · Nov 2019: $30.5M · 1st Form D
Awards before first raise: 7 awards

An association in public records, not a cause or a prediction.

Standing among 1449 peers

Line = median

Biotech · Molecule

Granted patents#16 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

ALEXANDER S. CUMBOExecutive OfficerNamed in SEC Form D filings
CLAUDE W. NICAISEDirectorNamed in SEC Form D filings
DAVID TYRONNE HOWTONExecutive OfficerNamed in SEC Form D filings
DAVID TYRONNE HOWTONExecutive OfficerNamed in SEC Form D filings
DOUGLAS S. INGRAMExecutive Officer, DirectorNamed in SEC Form D filings
DOUGLAS S. INGRAMExecutive Officer, DirectorNamed in SEC Form D filings

Show all 19 people

GILMORE TYRONNE O'NEILLExecutive OfficerNamed in SEC Form D filings
HANS W. WIGZELLDirectorNamed in SEC Form D filings
JOHN C. MARTINDirectorNamed in SEC Form D filings
JOHN C. MARTINDirectorNamed in SEC Form D filings
MARY ANN W. GRAYDirectorNamed in SEC Form D filings
M. KATHLEEN BEHRENSDirectorNamed in SEC Form D filings
MICHAEL W. BONNEYDirectorNamed in SEC Form D filings
MICHAEL W. BONNEYDirectorNamed in SEC Form D filings
M. KATHLEEN BEHRENSDirectorNamed in SEC Form D filings
RICHARD J. BARRYDirectorNamed in SEC Form D filings
RICHARD J. BARRYDirectorNamed in SEC Form D filings
SANDESH MAHATMEExecutive OfficerNamed in SEC Form D filings
WILLIAM CIAMBRONEExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 10 granted of 40

Sep 10, 2026PendingSuspension Mode Seed Train Development For Adherent CellsUSPTOApplication 19538762
Jun 16, 2026GrantedDose Packaging System For Medication And Method Of Storing Dose ThereinUSPTOUS 12,653,756
Jun 11, 2026PendingMethods For Treating Muscular DystrophyUSPTOApplication 19253103

Show all 40 patent records

Suspension Mode Seed Train Development For Adherent CellsSep 10, 2026 · Application 19538762Pending
Dose Packaging System For Medication And Method Of Storing Dose ThereinJun 16, 2026 · US 12,653,756Granted
Methods For Treating Muscular DystrophyJun 11, 2026 · Application 19253103Pending
Pompe Disease Mouse Model Generation, Characterization And Methods Of UseMay 7, 2026 · Application 19114326Pending
Methods For Analyzing Aav Capsid ProteinsMay 5, 2026 · US 12,618,850Granted
Compositions For Treating Muscular DystrophyApr 30, 2026 · Application 18966357Pending
Compositions For Treating Muscular DystrophyApr 30, 2026 · Application 18814323Pending
Aav Transfer CassetteApr 28, 2026 · US 12,611,436Granted
Recombinant Aav Vectors For Treating Muscular DystrophyApr 9, 2026 · Application 19114103Pending
Suspension Mode Seed Train Development For Adherent CellsMar 17, 2026 · US 12,577,540Granted
Antisense Oligomer CompoundsMar 12, 2026 · Application 19086656Pending
Genetic Constructs For Gene EditingMar 5, 2026 · Application 19181618Pending
Peptide Oligonucleotide ConjugatesJan 15, 2026 · Application 19029784Pending
Methods For Treating Muscular Dystrophy With CasimersenJan 8, 2026 · Application 19050625Pending
Methods Of Treating Muscular DystrophyJan 1, 2026 · Application 18876051Pending
Muscle Tropic RaavDec 4, 2025 · Application 19223409Pending
Treatment Of Genetic Neurological Conditions With Genomic EditingNov 27, 2025 · Application 19187380Pending
Exon Skipping Oligomers For Muscular DystrophySep 18, 2025 · Application 19071514Pending
Processes For Preparing Phosphorodiamidate Morpholino OligomersSep 4, 2025 · Application 19060080Pending
Adeno-associated Virus Antibodies And Fragments ThereofAug 19, 2025 · US 12,391,745Granted
Exon Skipping Oligomer Conjugates For Muscular DystrophyAug 5, 2025 · US 12,377,150Granted
Modified Antisense Oligomers For Exon Inclusion In Spinal Muscular AtrophyJul 31, 2025 · Application 18813696Pending
Exon Skipping Compositions For Treating Muscular DystrophyJul 24, 2025 · Application 18885116Pending
Phosphorodiamidate Morpholino Oligomer ConjugatesJun 19, 2025 · Application 18842988Pending
Exon Skipping Oligomer Conjugates For Muscular DystrophyJun 5, 2025 · Application 18744061Pending
Antisense Oligomers And Methods Of Using The Same For Treating Diseases Associated With The Acid Alpha-glucosidase GeneMay 29, 2025 · Application 18910901Pending
Multiple Exon Skipping Compositions For DmdMay 15, 2025 · Application 18778132Pending
Phosphorodiamidate Morpholino OligomersMay 13, 2025 · US 12,297,219Granted
Exon Skipping Compositions For Treating Muscular DystrophyMay 8, 2025 · Application 18885088Pending
Treatment Methods For Muscular DystrophyApr 29, 2025 · US 12,286,630Granted
Processes For Preparing Phosphorodiamidate Morpholino OligomersMar 25, 2025 · US 12,258,362Granted
Exon Skipping Oligomers And Oligomer Conjugates For Muscular DystrophyMar 20, 2025 · Application 18634360Pending
Exon Skipping Oligomers And Oligomer Conjugates For Muscular DystrophyMar 20, 2025 · Application 18440684Pending
Peptide Oligonucleotide ConjugatesMar 4, 2025 · US 12,239,715Granted
Antisense Oligomers For Treatment Of Chronic Kidney DiseaseFeb 27, 2025 · Application 18647899Pending
Exon Skipping Oligomer Conjugates For Muscular DystrophyFeb 27, 2025 · Application 18807055Pending
Peptide Oligonucleotide ConjugatesFeb 20, 2025 · Application 18658614Pending
Production Of Recombinant Aav Vectors For Treating Muscular DystrophyJan 16, 2025 · Application 18562148Pending
Antisense Oligonucleotides Having One Or More Abasic UnitsDec 26, 2024 · Application 18693769Pending
Antisense-induced Exon Exclusion In Type Vii CollagenDec 19, 2024 · Application 18410720Pending

AchaogenSimilar federal contract value in Biotech · $214M in contracts
Ginkgo BioworksSimilar federal contract value in Biotech · $191M in contracts
Cellerant Therapeutics, Inc.Similar federal contract value in Biotech · $185M in contracts
CELLPHIRE, INCSimilar federal contract value in Biotech · $162M in contracts
VEDANTA BIOSCIENCES, INC.Similar federal contract value in Biotech · $99.1M in contracts
CONTINUUS Pharmaceuticals, Inc.Similar federal contract value in Biotech · $73.7M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.